Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...

Vivani Medical, Inc. (NASDAQ:VANI) announced the administration of its first GLP-1 (exenatide, NPM-115) implant in the ...

Customers can expect a rate hike up to 14 percent as employee welfare costs surge related to Ozempic and drugs like it.

Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

Semaglutide shows promise in reducing alcohol cravings and consumption. Could it be a future treatment for AUD?

Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost ...

(HealthDay News) — Low-dose semaglutide seems to reduce craving and certain drinking outcomes in alcohol use disorder (AUD), according to a study published online Feb. 12 in JAMA Psychiatry.

Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating ...

HFpEF outcomes were improved with semaglutide, compared with placebo, among patients with obesity-related HFpEF and type 2 diabetes.

NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients ...

FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...

Novo Nordisk launches NovoCare Pharmacy, offering uninsured and cash-paying patients Wegovy for $499 per month. The service ...